Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow

Haematologica

Volumn 88, Issue 9, 2003, Pages 1072-1074

  Steensma, David P ^a,b   Mesa, Ruben A ^a   Reeder, Terra L ^a   Tefferi, Ayalew ^a   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

MAPK; MEK inhibitors

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROID CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYELODYSPLASTIC SYNDROME; SIGNAL TRANSDUCTION;

BENZAMIDES; BONE MARROW; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYELODYSPLASTIC SYNDROMES; TUMOR CELLS, CULTURED;

EID: 0141702130     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997;11:479-84.
2. Kim SC, Hahn JS, Min YH, Yoo NC, Ko YW, Lee WJ. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 1999;93:3893-9.
3. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-9.
4. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6.
5. Lo Russo PM, Adjei AA, Meyer MB, Wozniak A, Gadgeel SM, Hanson LJ, et al. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 2002;21:81a[abstract].
6. Eaves C, Lambie K. In: Atlas of human hematopoietic colonies. StemCell Technologies Inc., Vancouver. 1995.
7. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-601.
8. Theodosiou A, Ashworth A. MAP kinase phosphatases. Genome Biol 2002;3:reviews3009.
9. Meighan-Mantha RL, Wellstein A, Riegel AT. Differential regulation of extracellular signal-regulated kinase 1 and 2 activity during 12-O-tetradecanoylphorbol 13-acetate induced differentiation of HL-60 cells. Exp Cell Res 1997;234:321-8.